NEW YORK – Bio-Techne said Tuesday that its fiscal 2020 second quarter revenues rose 6 percent year over year, due in part to strong growth in its Diagnostics and Genomics businesses.
For the three months ended Dec. 31, 2019, the firm posted $184.9 million in revenues, up from $174.5 million a year ago but below analysts' average estimate of $191.2 million.